RP-L401

N/A

Report date: 2023/10/26 17:04:41

Base Information

Drug NameRP-L401
Drug Alias NameAutologous CD34+ Enriched Cells Transduced With a LV Vector Encoding the TCIRG1 GeneRP-L401
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionGene transferenceCell replacements
TargetsNot applicable
Therapy Area/IndicationsOsteopetrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRocket Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRocket Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsOsteopetrosis

Other Information

ATC CodeN/A
Related LinksN/A